Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis

References

• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60:218–224.
   PubMed Web of Science ®Google Scholar
• Russell CB, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Investig Dermatol. 2010;130:S46–S46.
   Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–493.
   PubMed Web of Science ®Google Scholar
• Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti–IL-17 receptor monoclonal antibody. J Immunol. 2014;192:3828–3836.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21:211–215.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. InMAbs. 2010;2:256–265.
   Google Scholar
• Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;19:949–958.
   Google Scholar
• Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146:127–132.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31e1.
   Web of Science ®Google Scholar
• Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics. 2009;19:383–387.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F (ab′) 2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60:41–48.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, de Groot E, Nurmohamed MT, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12:R221.
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947–1955.
   PubMed Web of Science ®Google Scholar
• Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777–787.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–1090.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412–421.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36.e21.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41:1039–1046.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–411.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183–1190.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81:44–52.
   PubMed Web of Science ®Google Scholar
• Osamu N, Hirotaka N, Koji S, et al. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study. J Dermatol Sci. 2014;75:201–204.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12:217.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–1468.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Kalden JR. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13:707.
   PubMed Web of Science ®Google Scholar
• Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372:196–203.
   PubMed Web of Science ®Google Scholar
• Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24:306–311.
   PubMed Web of Science ®Google Scholar
• Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies – toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20:431–435.
   PubMed Web of Science ®Google Scholar
• Van Stappen T, Brouwers E, Vermeire S, et al. Validation of a sample pretreatment protocol to convert a drug‐sensitive into a drug‐tolerant anti‐infliximab antibody immunoassay. Drug Test Analysis. 2017;9:243–247.
   PubMed Web of Science ®Google Scholar
• Bian S, Ferrante M, Gils A. Validation of a drug-resistant anti-adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of adalimumab. AAPS J. 2017;19:468–474.
   PubMed Web of Science ®Google Scholar
• Van Stappen T, Casteele NV, Van Assche G, et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2018;67:818–826.
   PubMed Web of Science ®Google Scholar
• Bourdage JS, Cook CA, Farrington DL, et al. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327:10–17.
   PubMed Web of Science ®Google Scholar
• Van Schie KA, Hart MH, de Groot ER, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74:311–314.
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2). Br J Dermatol. 2013;168:1325–1334.
   PubMed Web of Science ®Google Scholar
• Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164:434–441.
   PubMed Web of Science ®Google Scholar
• Menting SP, van Lümig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150:130–136.
   PubMed Web of Science ®Google Scholar
• Hoffmann JH, Hartmann M, Enk AH, et al. Autoantibodies in psoriasis as predictors for loss of response and anti‐infliximab antibody induction. Br J Dermatol. 2011;165:1355–1358.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–542.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–1847.
   PubMed Web of Science ®Google Scholar
• Vena G, Loconsole F, Mastrandrea V, et al. Therapeutic Hotline: re‐induction may be useful to manage psoriasis relapse during long‐term maintenance treatment with infliximab: a retrospective analysis. Dermatol Therapy. 2010;23:199–202.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–1231.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–1915.
   PubMed Web of Science ®Google Scholar